Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2020

01-12-2020 | Breast Cancer | Correction

Correction to: Trastuzumab-induced upregulation of a protein set in extracellular vesicles emitted by ErbB2-positive breast cancer cells correlates with their trastuzumab sensitivity

Authors: Arik Drucker, Byong Hoon Yoo, Iman Aftab Khan, Dongsic Choi, Laura Montermini, Xiaoyang Liu, Sanja Jovanovic, Tallal Younis, Kirill V. Rosen

Published in: Breast Cancer Research | Issue 1/2020

Login to get access

Excerpt

Correction to: Breast Cancer Res 22, 105 (2020) …
Literature
1.
Metadata
Title
Correction to: Trastuzumab-induced upregulation of a protein set in extracellular vesicles emitted by ErbB2-positive breast cancer cells correlates with their trastuzumab sensitivity
Authors
Arik Drucker
Byong Hoon Yoo
Iman Aftab Khan
Dongsic Choi
Laura Montermini
Xiaoyang Liu
Sanja Jovanovic
Tallal Younis
Kirill V. Rosen
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2020
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-020-01358-8

Other articles of this Issue 1/2020

Breast Cancer Research 1/2020 Go to the issue

Research article

Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer

Research article

Cathepsin V suppresses GATA3 protein expression in luminal A breast cancer

Research article

Serum exosomal-annexin A2 is associated with African-American triple-negative breast cancer and promotes angiogenesis

Research article

Impact of a ketogenic diet intervention during radiotherapy on body composition: III—final results of the KETOCOMP study for breast cancer patients

Research article

Insulin resistance contributes to racial disparities in breast cancer prognosis in US women

Correction

Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits